27 September 2013Americas

Judge denies AstraZeneca’s bid to squash pay-for-delay challenge

A federal judge has denied AstraZeneca’s motions to dismiss claims challenging its pay-for-delay deals with three generic pharmaceutical companies in connection to heartburn drug Nexium.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

AstraZeneca and Ranbaxy win ‘pay-for-delay’ case

8 December 2014 A US court has spared drug companies AstraZeneca and Ranbaxy Laboratories a potentially hefty fine after ruling that a ‘pay-for-delay’ deal between them did not violate antitrust grounds.

US Supreme Court backs ‘rule-of-reason’ for pay-for-delay

17 June 2013 A majority of the US Supreme Court has ruled that the US Federal Trade Commission should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.

More on this story

AstraZeneca and Ranbaxy win ‘pay-for-delay’ case

8 December 2014 A US court has spared drug companies AstraZeneca and Ranbaxy Laboratories a potentially hefty fine after ruling that a ‘pay-for-delay’ deal between them did not violate antitrust grounds.

US Supreme Court backs ‘rule-of-reason’ for pay-for-delay

17 June 2013 A majority of the US Supreme Court has ruled that the US Federal Trade Commission should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.

More on this story

AstraZeneca and Ranbaxy win ‘pay-for-delay’ case

8 December 2014 A US court has spared drug companies AstraZeneca and Ranbaxy Laboratories a potentially hefty fine after ruling that a ‘pay-for-delay’ deal between them did not violate antitrust grounds.

US Supreme Court backs ‘rule-of-reason’ for pay-for-delay

17 June 2013 A majority of the US Supreme Court has ruled that the US Federal Trade Commission should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.

More features

In-house with Bayer: ‘Focus on quality early and stay close to inventors’

Explainer: ARIPO’s role in Plant Variety Protection

J&J sues over schizophrenia drug generic following patent victory

WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’

Powell Gilbert launches Düsseldorf office with leading patent litigator

Startups toolkit: Why investors want more than patents

J&J fends off generic schizophrenia drug bids